What the 2026 FDA enforcement record means for research-peptide websites
FDA's 2026 enforcement focus has been on marketing: claims implying sameness with approved drugs, implied FDA approval or evaluation, and product branding that obscures who makes a drug. Thirty telehealth companies received warning letters on 3 March 2026 and twenty-five more on 16 June 2026. Research-peptide sellers are not the addressees of those letters, but the same claim types appear in the retatrutide letters and in the 2026 litigation, and they are the ones a peptide website should not make.
What FDA said, and to whom
The March and June 2026 letters went to telehealth companies marketing compounded GLP-1 drugs (compounded drugs are not FDA-approved, which is the point of the letters). FDA's stated concerns were promotional claims that compounded products are the same as or equivalent to approved drugs, claims that imply FDA has approved or evaluated a compounded product, and advertising drug products under a company's own brand without qualification. FDA also published a page on what to know when promoting compounded drugs. Separately, FDA has issued warning letters concerning retatrutide, an investigational compound with no approved version.
Why a research-peptide seller should care
The claim types are portable. "Same active ingredient as [approved drug]", "pharmaceutical grade" used to imply approval, "clinically proven" for a research compound, and any efficacy or quantity statement about a product labelled research use only are the phrases we treat as red on peptide money pages. They are also the phrases answer engines and regulators search for: in our captures of assistant behaviour on supplier questions, the model's own searches appended "FDA", "unapproved" and "research use only" to compound names.
What we changed
- A dated rule store with green, amber, red, changed and unknown statuses for terms and claims, each with a source, jurisdiction and review date.
- A first-pass check on every page, product description, comparison table, FAQ, alt text, anchor and CTA before it reaches the client, reporting "review required" with the rule and source, never "illegal".
- Comparison content that describes and cites rather than equates.
Escalation
Whether a given claim is lawful for your product and your customers is a question for your counsel. This brief records what FDA has said publicly and how we write because of it.
Sources
- FDA: FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s (2026-03-03) — https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1-s
- FDA: What to know when promoting compounded drugs (guidance page; compounded drugs are not FDA-approved) — https://www.fda.gov/drugs/human-drug-compounding/what-know-when-promoting-compounded-drugs
- FDA warning letters index — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
PeptidesSEO provides search-marketing services and publishes search-marketing analysis. We are not physicians, pharmacists, lawyers or regulatory consultants, and nothing on this site is medical, legal or regulatory advice. Clients remain responsible for obtaining qualified advice about their products, claims, jurisdictions and operations.